@article{8edecade4897453b86ea0ef86fe5ba79,
title = "Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer",
abstract = "This phase III study examined efficacy of the synthetic Toll-like receptor 9-activating oligodeoxynucleotide PF-3512676 in combination with standard paclitaxel/carboplatin chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC).",
author = "Vera Hirsh and Luis Paz-Ares and Michael Boyer and Rafael Rosell and Gary Middleton and Eberhardt, {Wilfried E E} and Aleksandra Szczesna and Pavel Reiterer and Mansoor Saleh and Oscar Arrieta and Emilio Bajetta and Webb, {Roy T} and Johannes Raats and Benner, {Rebecca J} and Camilla Fowst and Meech, {Sandra J} and David Readett and Schiller, {Joan H}",
year = "2011",
doi = "10.1200/JCO.2010.32.8971",
language = "English",
volume = "29",
pages = "2667--74",
journal = "Journal of Clinical Oncology ",
issn = "1527-7755",
publisher = "American Society of Clinical Oncology",
number = "19",
}